Patterns of clinical presentation of climacteric syndrome and total body composition in women with menopausal metabolic syndrome

Introduction. Modern gynecological endocrinology widely discusses various disorders accompanying the onset of menopause. Metabolic disorders are one of the leading risk factors for the development of ischemic heart disease and vascular dystonia in menopausal women. That is why the drugs prescribed as part of menopausal hormone therapy are contraindicated for patients with severe metabolic disorders and predisposition to thrombosis. Women with a normal body mass index may develop the menopausal metabolic syndrome, since its presentations largely depend on the total body composition and the specific gravity of visceral adipose tissue.

Aim. To assess the patterns of clinical presentation of menopause in women with metabolic menopausal syndrome.

Materials and methods. In the furtherance of that aim, we examined 184 women who were in menopause 1 to 5 years at the age of 52 to 57 years (average age 54.2 ± 0.5 years). Of these, 87 were diagnosed with metabolic syndrome – they were included in the main group. The comparison group included 97 menopausal women without metabolic disorders.

Results and discussion. We assessed the severity of clinical presentations and the total body composition of the patients in the selected groups. It has been established that the body mass index cannot serve as a criterion for evaluation of metabolic processes, despite the sufficient simplicity of its computation.

Conclusions. The authentic view of the risks of metabolic disorders in menopausal women requires the study of total body composition.

1. Balanova Yu.A., Shalnova S.A., Deev A.D. Obesity in the Russian population – prevalence and associations with risk factors for chronic non-communicable diseases. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;23(6):123–130. (In Russ.) https://doi.org/10.15829/1560-4071-2018-6-123-130.

2. Elraiyah T., Sonbol M.B., Wang Z., Khairalseed T., Asi N., Undavalli C. et al. Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3543–3550. https://doi.org/10.1210/jc.2014-2262.

3. Andreeva E.N., Sheremetyeva E.V. Mental aspects and violation of fat metabolism in menopause. Akusherstvo i ginekologiya = Obstetrics and Gynecology. 2019;9:165–172. (In Russ.) https://doi.org/10.18565/aig.2019.9.165-172.

4. Franco O.H. , Muka T., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R., Kavousi M. Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and meta-analysis. Maturitas. 2015;81(3):35. https://doi.org/10.1016/j.maturitas.2015.04.016.

5. Greendale G.A., Sternfeld B., Huang M., Han W., Karvonen-Gutierrez C., Ruppert K. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. https://doi.org/10.1172/jci.insight.124865.

6. Hodis H.N., Mack W.J. Cardiovascular risk after withdrawal of hormone therapy. Menopause. 2018;25(4):365–367. https://doi.org/0.1097/GME.0000000000001076.

7. Foster M.C., Hwang S.J., Larson M.G., Lichtman J.H., Parikh N.I., Vasan R.S. et al. Overweight, obesity and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008;52(1):39–48. https://doi.org/10.1053/j.ajkd.2008.03.003.

8. Shalina M.A. Metabolic syndrome in older women. Zhurnal akusherstva i zhenskikh bolezney = Journal of Obstetrics and Women’s Diseases. 2019;68(3):81–88. (In Russ.) https://doi.org/10.17816/JOWD68381-88.

9. Protasova A.E., Yureneva S.V., Bayramov N.N., Kompedina V.I. Menopause, obesity and comorbidity: the possibilities of menopausal hormone therapy. Akusherstvo i ginekologiya = Obstetrics and Gynecology. 2019;(5):43–48. (In Russ.) https://doi.org/10.18565/aig.2019.5.43-48.

10. Bikmeeva A.A., Karyagina N.T. Influence of leptin and adiponectin on reproductive dysfunctions in women with obesity. Mezhdunarodnyy studencheskiy nauchnyy vestnik = International Student Scientific Bulletin. 2018;(4–1):16–19. (In Russ.) Available at: https://eduherald.ru/ru/article/view?id=18605.

11. Blümel J.E., Fica J., Chedraui P., Mezones-Holguín E., Zuñiga M.C., Witis S. et al. Sedentary lifestyle in middle-aged women is associated with severe menopausal symptoms and obesity. Menopause. 2016;23(5):488–493. https://doi.org/10.1097/GME.0000000000000575.

12. Hodis H.N., Sarrel P.M. Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? Climacteric. 2018;21(6):521–528. https://doi.org/10.1080/13697137.2018.1514008.

13. Hofmeier S.M., Runfola C.D., Sala M., Gagne D.A., Brownley K.A., Bulik C.M. Body Image, Aging, and Identity in Women Over 50: The Gender and Body Image (GABI) Study J Women Aging. J Women Aging. 2017;29(1):3–14. https://doi.org/10.1080/08952841.2015.1065140.

14. Islam R.M., Bell R.J., Green S., Page M.J., Davis S.R. Safety and efcacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. https://doi.org/10.1016/S2213-8587(19)30189-5.

15. Boardman, H.M., Hartley L., Eisinga A., Main C., Roqué I.M., Figuls X. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. https://doi.org/10.1002/14651858.CD002229.pub4.

16. Chen G.C., Arthur R., Iyengar N.M., Kamensky V., Xue X., Wassertheil-Smoller S. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur Heart J. 2019;40(34):2849–2855. https://doi.org/10.1093/eurheartj/ehz391.

17. Chlebowski R.T., Mortimer J.E., Crandall C.J., Pan K., Manson J.E., Nelson R. et al. Persistent vasomotor symptoms and breast cancer in the Women’s Health Initiative. Menopause. 2018;26(6):578–587. https://doi.org/10.1097/GME.0000000000001283.

18. Chlebowski R.T., Luo J., Anderson G.L., Barrington W., Reding K., Simon M.S. et al. Weight loss and breast cancer incidence in postmenopausal women. Cancer. 2019;125(2):205–212. https://doi.org/10.1002/cncr.31687.

19. Eisenlohr-Moul Т.А., Rubinow D.R., Schrubbe L., Schrubbe L., Girdler S.S. Naturally Occurring Changes in Estradiol Concentrations in the Menopause Transition Predict Morning Cortisol and Negative Mood in Perimenopausal Depression. Girdler. Clin Psychol Sci. 2016;4(5):919–935. https://doi.org/10.1177/2167702616647924.

20. Lang T., Altman D. Basic statistical reporting for articles published in clinical medical journals: the SAMPL Guidelines. In: Smart P., Maisonneuve H., Polderman A. (eds). Science Editors’ Handbook, European Association of Science Editors; 2013. Available at: https://www.equator-network.org/wp-content/uploads/2013/07/SAMPL-Guidelines-6-27-13.pdf.

21. Iyengar N.M., Arthur R., Manson J.E., Chlebowski R.T., Kroenke C.H., Peterson L. et al. Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: A secondary analysis of a randomized clinical trial and observational study. JAMA Oncol. 2019;5(2):155–163. https://doi.org10.1001/jamaoncol.2018.5327.